NASDAQ : ARCT
Arcturus Therapeutics Holdings Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 11.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 313.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 285.08M |
| Enterprise Value | 116.53M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 28.42M |
| Shares Outstanding | 28.42M |
| Shares Change (YoY) | +3.47% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 74.48% |
| Float | 26.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.68 |
| Forward PS | 17.47 |
| PB Ratio | 1.82 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.88 |
| Quick Ratio | 5.76 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11,366.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.31% |
| Return on Assets (ROA) | -23.96% |
| Return on Invested Capital (ROIC) | -28.24% |
| Return on Capital Employed (ROCE) | -53.62% |
| Weighted Average Cost of Capital (WACC) | 16.69% |
| Revenue Per Employee | $264,577 |
| Profits Per Employee | -$840,324 |
| Employee Count | 111 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -4,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.48 |
| 52-Week Price Change | -0.70% |
| 50-Day Moving Average | 13.54 |
| 200-Day Moving Average | 9.01 |
| Relative Strength Index (RSI) | 39.19 |
| Average Volume (20 Days) | 655,020 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.46M |
| Short Previous Month | 5.38M |
| Short % of Shares Out | 19.21% |
| Short % of Float | 20.88% |
| Short Ratio (days to cover) | 6.99 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 29.37M |
| Gross Profit | -57.42M |
| Operating Income | -102.29M |
| Pretax Income | -93.28M |
| Net Income | -93.28M |
| EBITDA | -99.55M |
| EBIT | -102.29M |
| Loss Per Share | -$3.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 191.48M |
| Total Debt | 22.93M |
| Net Cash | 168.55M |
| Net Cash Per Share | $5.93 |
| Equity (Book Value) | 171.81M |
| Book Value Per Share | 6.04 |
| Working Capital | 163.63M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -72.73M |
| Capital Expenditures | -93,000 |
| Depreciation & Amortization | 2.75M |
| Net Borrowing | n/a |
| Free Cash Flow | -72.82M |
| FCF Per Share | -$2.56 |
Margins
| Measure | Value |
|---|
| Gross Margin | -195.50% |
| Operating Margin | -348.32% |
| Pretax Margin | -317.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.47% |
| Shareholder Yield | -3.47% |
| Earnings Yield | -33.17% |
| FCF Yield | -23.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.80 |
| Price Target Difference | 137.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -19.99% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.68 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |